Austin Tutor
Internal Medicine · New Orleans, LANPI 1710545751
Payments from drug & device makers
Across 177 payments — averaging $40.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$1K
- Abbott$693
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$489
- Abiomed$472
- Novo Nordisk$360
- plus $2K from 15 others
What the payments were for
- Travel & lodging$2,19731%
- Food & beverage$4,98069%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $1,710 |
| Boston Scientific | 10 | $1,408 |
| Abbott | 26 | $693 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $489 |
| Abiomed | 15 | $472 |
| Novo Nordisk | 13 | $360 |
| Kestra Medical Technology Services, Inc. | 14 | $353 |
| Novartis | 15 | $307 |
| Edwards Lifesciences | 3 | $291 |
| Pfizer | 12 | $208 |
| Inari Medical, Inc. | 3 | $202 |
| AstraZeneca | 9 | $159 |
| E.r. Squibb & Sons, L.L.C. | 7 | $137 |
| Amgen | 6 | $117 |
| Boehringer Ingelheim | 4 | $102 |
| Johnson & Johnson | 3 | $50 |
| Biosense Webster, Inc. | 1 | $38 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Cook Medical LLC | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,177 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $14,851 |
| Metoprolol Succinate | 31 | $335 |
| Nifedipine ErNifedipine | 18 | $324 |
| Atorvastatin Calcium | 34 | $263 |
| ClopidogrelClopidogrel Bisulfate | 21 | $209 |
| Ezetimibe | 17 | $203 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 15 | $199 |
| Carvedilol | 29 | $162 |
| Rosuvastatin Calcium | 12 | $153 |
| Hydrochlorothiazide | 16 | $132 |
| Furosemide | 24 | $92 |
| Amlodipine Besylate | 18 | $72 |
| Torsemide | 13 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $208 | $14,85118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- William SmithNew Orleans$50.5M
- Brian LewisNew Orleans$2M
- Steven DeitelzweigNew Orleans$939K
- Lydia BazzanoNew Orleans$892K
- Eboni Price-HaywoodNew Orleans$659K
- Susan Lewis AbdalianNew Orleans$301K
- Eduardo RodriguezNew Orleans$167K
- Shigeki SaitoNew Orleans$120K
- Jonathan GugelNew Orleans$95K
- Keith WinfreyNew Orleans$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.